Hot Sliver Stocks To Watch Right Now

Hot Sliver Stocks To Watch Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its core product programs under clinical or pre-clinical development include ALN-TTR, a Phase I clinical trial program for the treatment of transthyretin-mediated amyloidosis; ALN-APC, a Phase I clinical trial program for the treatment of hemophilia; ALN-PCS for the treatment of severe hypercholesterolemia; ALN-HPN, a pre-clinical development for the treatment of refractory anemia; and ALN-TMP, a pre-clinical development for the treatment of hemoglobinopathies, including beta-thalassemia and sickle cell anemia. The company?s partner-based programs comprise ALN-RSV01, a Phase II clinical trial program for the treatment of respiratory syncytial virus infection; ALN-VSP, a Phase I clinical trial completed program for the treatment of liver cancers; and ALN-HTT, a pre-clinical development for the treatment of H untington?s disease. It has strategic alliances with Novartis Pharma AG; F. Hoffmann-La Roche Ltd; Takeda Pharmaceutical Company Limited; Isis Pharmaceuticals, Inc.; Medtronic Inc.; Kyowa Hakko Kirin Co., Ltd.; and Cubist Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Advisors' Opinion:

• [By John Udovich]

  Small cap hepatitis stock Achillion Pharmaceuticals, Inc (NASDAQ: ACHN) saw shares jump on Monday only to then have a minor implosion on Tuesday – meaning its worth taking a look at that hiccup and the history of hiccups or successes from other small cap hepatitis stocks like Idenix Pharmaceuticals Inc (NASDAQ: IDIX), Arrowhead Research Corp (NASDAQ: ARWR) and Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY). It should be mentioned that Hepatitis A, B and C are viral infecti! ons that together affect an estimated 5% to 6% of Americans and while globally, 2 billion people (1 out of 3 people) have been infected with hepatitis B with  400 million people chronically infected plus 130–150 million people have chronic hepatitis C - meaning there is plenty of room for large and small cap players alike in the space.

• [By Garrett Cook]

  Alnylam Pharmaceuticals (NASDAQ: ALNY) shares were also up, gaining 20.89 percent to $88.07 after the company reported six-month clinical data from patisiran phase 2 OLE study in patients with familial amyloidotic polyneuropathy.

• [By Jake L'Ecuyer]

  Equities Trading UP
  Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) got a boost, shooting up early in the day, but settling on a gain of 40.40 percent to $92.96 after the company reported that it has acquired investigational RNAi Therapeutic assets from Merck (NYSE: MRK). Genzyme and Alnylam expanded their collaboration on rare genetic diseases.

• [By Jake L'Ecuyer]

  Equities Trading UP
  Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) got a boost, shooting up 53.25 percent to $101.47 after the company reported that it has acquired investigational RNAi Therapeutic assets from Merck (NYSE: MRK). Genzyme and Alnylam expanded their collaboration on rare genetic diseases.

source from Top Stocks For 2015:http://www.topstocksblog.com/hot-sliver-stocks-to-watch-right-now.html